86 related articles for article (PubMed ID: 20151639)
1. Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.
Larroque-Lombard AL; Todorova M; Golabi N; Williams C; Jean-Claude BJ
J Med Chem; 2010 Mar; 53(5):2104-13. PubMed ID: 20151639
[TBL] [Abstract][Full Text] [Related]
2. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
Rachid Z; Brahimi F; Katsoulas A; Teoh N; Jean-Claude BJ
J Med Chem; 2003 Sep; 46(20):4313-21. PubMed ID: 13678409
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effects of a specific mixture of nutrients in the multidrug-resistant human uterine sarcoma MES-SA/Dx5 and the drug-sensitive MES-SA cell lines.
Roomi MW; Kalinovsky T; Roomi NW; Rath M; Niedzwiecki A
Oncol Rep; 2012 Jan; 27(1):17-27. PubMed ID: 21947138
[TBL] [Abstract][Full Text] [Related]
4. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
5. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening.
Wesolowska O; Paprocka M; Kozlak J; Motohashi N; Dus D; Michalak K
Anticancer Res; 2005; 25(1A):383-9. PubMed ID: 15816562
[TBL] [Abstract][Full Text] [Related]
6. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
Choi JS; Kang NS; Min YK; Kim SH
Phytother Res; 2010 Jul; 24(7):1042-6. PubMed ID: 19960428
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
Al-Safadi S; Domarkas J; Han Y; Brahimi F; Jean-Claude BJ
Anticancer Drugs; 2012 Jun; 23(5):483-93. PubMed ID: 22421369
[TBL] [Abstract][Full Text] [Related]
8. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.
Traunecker HC; Stevens MC; Kerr DJ; Ferry DR
Br J Cancer; 1999 Nov; 81(6):942-51. PubMed ID: 10576649
[TBL] [Abstract][Full Text] [Related]
9. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
[TBL] [Abstract][Full Text] [Related]
10. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells.
Wang E; Lee MD; Dunn KW
J Cell Physiol; 2000 Aug; 184(2):263-74. PubMed ID: 10867652
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of half-mustard combi-molecules with fluorescence properties: correlation with EGFR status.
Rachid Z; Brahimi F; Domarkas J; Jean-Claude BJ
Bioorg Med Chem Lett; 2005 Feb; 15(4):1135-8. PubMed ID: 15686928
[TBL] [Abstract][Full Text] [Related]
14. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
Qiu Q; Domarkas J; Banerjee R; Katsoulas A; McNamee JP; Jean-Claude BJ
Anticancer Drugs; 2007 Feb; 18(2):171-7. PubMed ID: 17159603
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
Brahimi F; Rachid Z; McNamee JP; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
Biochem Pharmacol; 2005 Aug; 70(4):511-9. PubMed ID: 15982640
[TBL] [Abstract][Full Text] [Related]
16. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line.
Hua J; Mutch DG; Herzog TJ
Gynecol Oncol; 2005 Jul; 98(1):31-8. PubMed ID: 15921732
[TBL] [Abstract][Full Text] [Related]
17. Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism.
Park S; James CD
Cancer Res; 2003 Feb; 63(3):723-7. PubMed ID: 12566319
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of novel amino-substituted xanthenones and benzo[b]xanthenones: evaluation of their antiproliferative activity and their ability to overcome multidrug resistance toward MES-SA/D x 5 cells.
Kostakis IK; Pouli N; Marakos P; Skaltsounis AL; Pratsinis H; Kletsas D
Bioorg Med Chem; 2006 May; 14(9):2910-34. PubMed ID: 16376546
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs.
Angelini A; Iezzi M; Di Febbo C; Di Ilio C; Cuccurullo F; Porreca E
Oncol Rep; 2008 Oct; 20(4):731-5. PubMed ID: 18813811
[TBL] [Abstract][Full Text] [Related]
20. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
